Related to Does Clinical Success Mean Commercial Success for Cancer Vaccines?

• Gene Test Boom Faces Lawsuits
  Testing giant and two rivals clash in court, threatening to cloud a sunny growth forecast.
  
• Literature Review: New Combination of Targets Shows Promise for Leukemia
  Researchers looked at the combination of a CHK1 inhibitor and an HDAC inhibitor for their effect on AML cells.
  
• Eye on Cancer Biomarkers
  This insightful analysis of publications shows research trends and putative signatures for different cancer types.
  
• Cancer Biomarkers: Your Questions Answered
  Enal Razvi, Ph.D., replies to all comments posted in his report 'Eye on Cancer Biomarkers'
  
• Eye on Cord Blood for Cell Therapy
  A snapshot of this evolving market landscape.
  
• Literature Review: Probing Protein Oligomerization
  Researchers describe an assay to measure the allosteric effects of synthetic peptides on self-oligomerization of AGR2 protein.
  
• Ovarian Cancer Treatment Options Multiply
  Vaccines and PARP inhibitors are among the promising emerging therapies.
  
• 2009 in Review: Headline-Making Stories in the Biotech Industry
  Even though last year was marred by the economic crash, the life science sector showed significant progress.
  
• Combining Gene and Cell Therapy Is Arming Researchers with More Options for Cancer
  Recent news about success in three leukemia patients shows early-stage translation of basic research.
  
• Immune Response Markers for Cancer Vaccines Paint a Clearer Picture
  In trying to understand what constitutes an effective immune response, researchers find it’s all about T cells.
  
• CMOs Capitalizing on Experience to Develop Their Own Therapeutics
  A few pioneering contract manufacturing organizations are testing the drug development waters.
  
• 10 Predictions That Will Transform Healthcare
  Peer into GEN's crystal ball for a glimpse of what's to come.
  
• Will a Nonautologous Cancer Vaccine Be the Next to Make It Through Approval?
  In the race to mimic Dendreon’s success with Provenge, off-the-shelf products make for attractive opportunities.
  
• Getting Cancer Immunotherapeutics Approved
  It’s not just the FDA standing in the way.
  
• Dendreon’s $70M Investment in Production Capabilities Could Woo Firms without Similar Expertise
  If cell-based immune therapy Provenge receives FDA sanction, it may corner a large market share and expand the company’s prospects.
  
• How Provenge Laid the Groundwork for Developing and Regulating Cancer Vaccines
  FDA’s recently issued guidelines pull from more than 20 years of research and clinical experience.
  
• Autologous Immunotherapy Updates at ASCO Further Define Antitumor Immune Responses
  Biovest and Dendreon presented studies involving their respective vaccines in the neoadjuvant setting.
  
• Opinion: A Stem of Hope for Cancer Treatments
  Evidence mounts in favor of therapies targeting cancer stem cells.
  
• Vaccine Isotype Seems to Affect Clinical Outcome in Blood Cancer Trials
  New results presented at ASH will impact production of autologous immunotherapies.
  
• What Comes After Dendreon’s Provenge?
  Success of prostate cancer vaccine has ushered in a wave of autologous vaccine development.